Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04758234 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3549492 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT04758234 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 54 participants.
The verdict
NCT04758234, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in healthy participants. The blood tests will be performed to check how much LY3549492 gets into the bloodstream and how the body handles LY3549492. This study includes two parts and will last up to approximately 76 days for each participant, including screening.
Interventions
- DRUG Placebo
- DRUG LY3549492
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2021-02-22 |
| Est. Completion | 2022-01-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04758234
The ClinicalTrials.gov registry entry for NCT04758234 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04758234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04758234 about?
NCT04758234 is a clinical study titled "A Study of LY3549492 in Healthy Participants". The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in healthy participants. The blood tests will be performed to check how much LY3549492 gets into the bloodstream and how the body handles LY3549492. This study includes two parts and will last up to approximately ...
What is the current status of trial NCT04758234?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2021-02-22. Estimated completion is 2022-01-10.
What interventions are being tested in trial NCT04758234?
The interventions under investigation include: Placebo (DRUG), LY3549492 (DRUG).
Who is sponsoring clinical trial NCT04758234?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.